Indefinite Delivery Contract SPE2DU25D1059

Award Date 8/1/25
Last Date to Order 12/31/36
Ultimate Awardee
Not listed
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,999,999.00, will provide worldwide pharmaceutical support to various DoD customers, including the Defense Health Agency, Department of Defense, U.S. Coast Guard, and U.S. Naval Fleet, through the Pharmaceutical Prime Vendor Global Program...
This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, to provide a wide range of pharmaceutical products and medical supplies to support military healthcare programs globally. The $999,999,999 contract, which has a period of performance through December 2036, serves as a primary vehicle for the government to procure critical medical commodities including...
The Department of Defense (DoD) Defense Logistics Agency (DLA) Troop Support Medical has awarded an Indefinite Delivery Contract (IDC) valued at $999,999,999 to AmerisourceBergen Drug Corp to provide worldwide pharmaceutical support to DoD customers, including the Defense Health Agency, U.S. Coast Guard, and U.S. Navy. This 11-year IDC, running from November 2025 to November 2036, is part of the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) procurement, which will...
The Indefinite Delivery Contract (IDC) SPE2DR25D3404 was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $9,999,999,999, has an ultimate completion date of December 31, 2036 and serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally....
This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $9,999,999,999, is a single-award IDC with a period of performance running through December 31, 2036. The purpose of this contract is to establish Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) contracts to provide worldwide...
The Defense Logistics Agency (DLA) Troop Support Medical awarded a $999,999,999 Indefinite Delivery Contract (IDC) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, to provide worldwide pharmaceutical support to various DoD customers. This single-award IDC has a 30-month base period and three 30-month option periods, for a total period of performance through December 2036. The contract aims to establish Prime Vendor Contracts for the DLA Troop Support's Pharmaceutical Prime...
The Defense Logistics Agency (DLA) Troop Support Medical Supply Chain awarded a single-award Indefinite Delivery Contract (IDC) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, to provide worldwide pharmaceutical support to various DoD customers. The $999,999,999 IDC has a 30-month base period and three 30-month option periods, totaling a potential 10-year period of performance through December 2036. The contract aims to establish Prime Vendor Contracts for the...
The Defense Logistics Agency (DLA) Troop Support Medical Supply Chain awarded a $999,999,999 Indefinite Delivery Contract (IDC) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, to provide worldwide pharmaceutical support to various DoD customers. The IDC covers a 30-month base period with three 30-month option periods, totaling an estimated $30.3 billion in value across multiple regional contracts. This IDC, known as the Pharmaceutical Prime Vendor Global Program Generation...
This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at up to $4,999,999, has an ultimate completion date of December 31, 2036 and was awarded on August 1, 2025. The contract aims to establish Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) contracts to provide worldwide...
This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, with a ceiling value of $9,999,999,999. The contract is intended to establish Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) contracts to provide worldwide pharmaceutical support to various DoD customers, including the Defense Health Agency (DHA),...

This federal Indefinite Delivery Contract (IDC) award to Amerisourcebergen Drug Corp by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain aims to establish Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) contracts to provide worldwide pharmaceutical support to various DoD customers, including the Defense Health Agency (DHA), the U.S. Coast Guard, and other designated providers.

The $4,999,999 single-award IDC has an ultimate completion date of December 31, 2036 and will cover a comprehensive range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic areas. The contract is structured as a firm-fixed price, requirements-type contract with a 30-month base period and three 30-month option periods, with a total estimated value of $30.3 billion. The acquisition will be fully competitive, with the intent to make multiple regional awards to at least three different contractors to ensure resiliency and access to vital pharmaceuticals.

Generated 6/6/25, 9:51 AM